Navigation Links
Schering-Plough Announces Transition of Animal Health Leadership
Date:10/17/2008

KENILWORTH, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the transition of leadership of its Animal Health unit from Ruurd Stolp, D.V.M., Ph.D., to Raul E. Kohan, who was previously the Deputy Head of the Animal Health unit. In his role as senior vice president and president, Intervet/Schering-Plough Animal Health, Kohan will continue reporting to Fred Hassan, chairman and chief executive officer.

In this role, Kohan is responsible for overseeing the company's worldwide animal health business, which includes a range of pharmaceuticals, vaccines and services for food-producing and companion animals. The role is based in Boxmeer, the Netherlands, where the Animal Health unit is headquartered.

Kohan joined Schering-Plough in 1984 and has since held positions of increasing responsibility. He recently served as Deputy Head of Animal Health and senior vice president, Corporate Excellence and Administrative Services for Schering-Plough Corporation. Previously, Kohan's responsibilities included overseeing the company's Global Specialty Operations group, which comprised Animal Health and Consumer Health Care for Schering-Plough.

Kohan graduated from the General San Martin Military Academy, Argentina, and holds an M.B.A. degree in economics from the University of Buenos Aires.

Stolp will transition responsibilities to Kohan over the next several months. During his 21 years with Intervet, Stolp held various roles of increasing responsibility within the Animal Health unit. Previously, Stolp was president of Intervet International, a position he held since 2002.

"Ruurd and Raul played critical leadership roles in our successful combination of Organon BioSciences with Schering-Plough over the past year," said Hassan. "I thank Ruurd for his leadership, guidance and important contributions bringing our two companies together. Raul and I look forward to working with him in an advisory capacity."

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

Media Contact

Steve Galpin, Jr.

+1 908 298 7415

Sabine Schueller

+31 485 58 7085

Investor Contacts

Janet Barth

Joseph Romanelli

+1 908 298 7436


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
2. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
3. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
4. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
5. Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
6. Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
8. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
9. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
10. Schering-Plough CEO to Buy $2 Million in Common Shares
11. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Raton (PRWEB) , ... September 20, 2017 , ... In ... Daily Brain Booster has already been receiving positive feedback from customers trying the product ... months. , Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION” is the creation of published ... the field of addiction and homeless services, including more than a decade of ...
(Date:9/20/2017)... ... ... “Psalms of Humidity”: is a fascinating depiction of daily struggles and the ... closer to God. “Psalms of Humidity” is the creation of published author, David Waldrop, ... his life are the very same things that have shaped him into the man ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: